Objective To investigate the clinical efficacy of programmed cell death protein 1(PD-1)/programmed cell death 1 ligand 1(PD-L1)immunotherapy combined with AP regimen(pemetrexed plus cisplatin)in the treatment of advanced lung adenocarcinomas.Methods A retrospective analysis was conducted on the clinical data of 80 patients with advanced lung adenocarcinomas admitted in Cangzhou Central Hospital from February 2019 to February 2022.They were divided into the control group(40 patients)and combination group(40 patients)based on their treatment plans.All patients were managed by AP regimen,and those in observation group were additionally given PD-1/PD-L1(sintilimab)immunotherapy.The clinical efficacy,cellular immune indicators(CD3+,CD4+,CD8+,CD4+/CD8+),humoral immune indicators(immunoglobulin[Ig]A,IgG,IgM),inflammatory cytokine indicators(interleukin-6[IL-6],tumor necrosis factor-α[TNF-α],C-reactive protein[CRP])and adverse reactions were compared between the two groups.The overall survival(OS)and progression-free survival(PFS)were counted.Results After treatment,the disease control rate(DCR)of the combination group was significantly higher than that of the control group(P＜0.05).After treatment,CD3+,CD4+and CD4+/CD8+in the combination group were significantly higher than those before treatment,while CD8+was significantly lower than that before treatment(P＜0.05).After treatment,CD3+,CD4+and CD4+/CD8+in the control group were significantly lower than those before treatment,while CD8+was significantly higher than that before treatment(P＜0.05).After treatment,the IgA,IgG,and IgM levels in the combination group were significantly higher than those before treatment,while those in the control group were significantly lower than before treatment(P＜0.05).After treatment,the levels of IL-6,TNF-α,and CRP in both groups were significantly lower than before treatment,which were more pronounced in the combination group(P＜0.05).During the treatment,there was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).The median OS and PFS of the combination group were significantly longer than those of the control group(P＜0.05).Conclusion The combination of sintilimab immunotherapy and AP regimen has a good clinical efficacy in the treatment of advanced lung adenocarcinomas,which can protect the patients'immune function,reduce inflammatory reactions,and has good safety.
NETL
NSTL
万方数据
